CTONG's First Partner for Founding NGS Lab
In August 2016, Co-founded by Chinese Thoracic Oncology Group (CTONG) and Burning Rock Dx, the Next Generation Sequencing (NGS) Clinical Research Lab was duly inaugurated at Guangzhou International Bio Island. This lab is intended for non-profit clinical studies. The 3,000m2 lab comprises 19 independent labs and an office area, covers an intact NGS test process from sample library preparation, nucleic acid extraction, library building & sequencing to data analysis & report generating inclusive, adopts world-class sequencing equipment and complies with international standard management systems. Professor Wu Yilong, President Elect of Chinese Society of Clinical Oncology (CSCO), and Mr. Han Yusheng, CEO of Burning Rock Dx, unveiled a plaque to mark the inauguration of the lab.
Burning Rock and America illumina Co. (NASDDAQ: ILMN) declared a strategic cooperation in Guangzhou and San Diego officially and signed an agreement on jointly developing a tumor individualistic medical gene detection.
On August 24, 2015, Burning Rock and America illumina Co. (NASDDAQ: ILMN) declared a strategic cooperation in Guangzhou and San Diego officially and signed an agreement on jointly developing a tumor individualistic medical gene detection. Both sides will cooperate to develop a tumor molecular diagnosis kit geared to Chinese market and easy to operate. As part of their cooperation, Burning Rock will provide nucleic acid extraction, construction of gene bank and data analysis software, while illumina will provide NGS instrument and related reagents. America illumina Co. is a globally leading supplier of new generation of high-flux sequencing instrument, and a leading developer, manufacturer and marketer of life science kit and complete system used to analyze hereditary mutations and functions on a large scale. These systems have realized researches which we could not imagine years ago and made us nearer to the fulfillment of individualistic medicine.
Molecular Diagnostics Solutions
Burning Rock Dx is planning to develop genetic cancer testing based on the Agilent SureSelect targeting sequence capture system in China to provide more high-quality NGS-based molecular diagnostics solutions for Chinese cancer patients
On September 29, 2016, Burning Rock Dx announced the conclusion of an agreement with a global diagnostics and genomics leader Agilent Technologies. As agreed, Burning Rock Dx is planned to develop genetic cancer testing based on the Agilent SureSelect targeting sequence capture system in China to provide more high-quality NGS-based molecular diagnostics solutions for Chinese cancer patients, including noninvasive cancer testing, recurrence monitoring, early diagnosis and genetic susceptibility screening among others.
For building a platform for sharing and discussing precision diagnosis and treatment cases in real world, probing into the unknown and promoting precision diagnosis and treatment practice.
Initiated by Burning Rock Dx in February 2017, “FeiRanChengZhang Anti-cancer Precision Medicine Case Roadshow” was aimed at setting up a platform for sharing and discussion precision diagnosis and treatment cases in real world, probing into the unknown and promoting precision diagnosis and treatment practice. In 2017, the “FeiRanChengZhang” roadshow ended up with success. The roadshow involved 1,500+ medical professionals from 40+ top hospitals in 14 provinces and municipalities nationwide, where 60+ real world cases were shared. In 2018, Burning Rock Dx partnered with CSCO Young and Wu Jieping Medical Foundation to escalate the roadshow project in size, form and range. By expanding from lung cancer to a variety of cancers and from case sharing to similar case arraying, the project was redesigned to inspire inspiration in scientific research and more universal clinical advice to cases of the like. For that end, a panel of dozens of specialists led by Professor Wu Yilong will evaluate cases from a variety of dimensions including integrity, typicality, inspiration, etc. Finalized national outstanding cases will be granted with an incentive from “Wu Jieping-Burning Rock Dx Young Physician Seed Fund”.
Designated testing partner to CSCO and CAGC in lung cancer research
Molecular Diagnostics Solutions
Burning Rock’s reassuring strategic partner in liquid biopsy - QIAGEN China with ctDNA sample preparation technology and high product quality
On June 5, 2018, Burning Rock Dx agreed with QIAGEN China to establish a strategic partnership in liquid biopsy for circulating tumor DNA (ctDNA) in all respects. Burning Rock keeps demanding on quality to offer testing results that can be trusted by doctors and patients. QIAGEN, with its ctDNA sample preparation technology and high product quality and purification efficiency can help Burning Rock improve quality of nucleic acid extracted from samples to produce more accurate testing results. It is believed that the two firms together can introduce high-quality NGS-based anti-cancer molecular diagnostics solutions to doctors and patients in China.
AstraZeneca's sole strategic NGS lung cancer testing partner involved in ASTRIS research and L-moca Olaparib stage-IV clinical research (HRD) in China
In 2016, Burning Rock Dx turned into AstraZeneca's lung cancer NGS testing partner by concluding a strategic partnership with AstraZeneca China. Earlier in 2017, Burning Rock Dx co-launched China's first non-profit NGS project targeting ovarian cancer-- ”Love Me, Test Me” public-welfare BRCA testing project for ovarian cancer patients.